Sumitomo Pharma Co (4506.T) Stock Price
Sumitomo Pharma Co Price
Sumitomo Pharma Co (4506.T) Stock | ISIN JP3495000006 | WKN 858257. The current Sumitomo Pharma Co stock price is 1,418.5 JPY (2026). Revenue is 443.46 B JPY. Net income is 94.87 B JPY. The P/E ratio is 5.94. Market capitalization is 563.56 B JPY. Sumitomo Pharma Co operates in the Health sector.
Sumitomo Pharma Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Sumitomo Pharma Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sumitomo Pharma Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sumitomo Pharma Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Sumitomo Pharma Co Price |
|---|
Sumitomo Pharma Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Sumitomo Pharma Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M JPY) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M JPY) |
| NET INCOME (M JPY) |
| NET INCOME GROWTH (%) |
| DIVIDEND (JPY)DIV. (JPY) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Sumitomo Pharma Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sumitomo Pharma Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sumitomo Pharma Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Sumitomo Pharma Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sumitomo Pharma Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Sumitomo Pharma Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Sumitomo Pharma Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Sumitomo Pharma Co business model & stock analysis
Sumitomo Pharma Co SWOT Analysis
Strengths
Sumitomo Dainippon Pharma Co Ltd boasts several strengths that contribute to its success and market position. Firstly, the company has a robust product portfolio consisting of a wide range of pharmaceutical products, allowing it to cater to diverse customer needs. This diverse portfolio acts as a strong competitive advantage in the industry.
Secondly, Sumitomo Dainippon Pharma has a strong focus on research and development (R&D). The company invests significantly in R&D activities to develop innovative drugs and therapies, positioning itself as an industry leader in terms of scientific advancements and cutting-edge solutions.
Additionally, the company has a global presence with strategic partnerships and widespread distribution networks. This enables Sumitomo Dainippon Pharma to tap into various international markets and establish a strong foothold in different regions.
Weaknesses
Sumitomo Dainippon Pharma also faces some weaknesses that can impact its operations and growth. One weakness is the company's heavy reliance on a few key products for a significant portion of its revenue. This concentration exposes the company to risks such as patent expiration or market competition, which could potentially impact its financial performance.
Another weakness is the limited market share in certain geographies. While the company has a global presence, it may face challenges in penetrating and expanding its market reach in specific regions where it has less visibility or established competition.
Opportunities
Sumitomo Dainippon Pharma can leverage several opportunities to drive its growth and market position further. One opportunity lies in the increasing demand for healthcare and pharmaceutical products globally. The company can capitalize on this by expanding its product portfolio and exploring new therapeutic areas or markets.
Furthermore, advancements in technology and digital healthcare present opportunities for Sumitomo Dainippon Pharma. Embracing digital solutions, such as telemedicine platforms or personalized medicine, can enhance patient experiences, improve treatment outcomes, and potentially open new revenue streams for the company.
Threats
Sumitomo Dainippon Pharma faces certain threats that may impact its business operations. One key threat is the stringent regulations and compliance requirements within the pharmaceutical industry. Non-compliance or changes in regulations can lead to delays in product launches, increased costs, or even legal issues, which can significantly impact the company's operations and reputation.
Additionally, the presence of intense competition in the pharmaceutical market poses a threat to Sumitomo Dainippon Pharma. Rival companies, with established market positions, strong product pipelines, or larger marketing budgets, can potentially outperform or outmaneuver the company in terms of market share, customer acquisition, and brand recognition.
Sumitomo Pharma Co Eulerpool Fair Value
Sumitomo Pharma Co historical P/E ratio, EBIT multiple, and P/S ratio
Sumitomo Pharma Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Sumitomo Pharma Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Sumitomo Pharma Co Dividend History
35 years of dividend payments
Sumitomo Pharma Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Sumitomo Pharma Co Earnings Estimates
Sumitomo Pharma Co Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/13/2024 | -74.29JPY | 92.91 BJPY | 2024 Q4 |
| 1/29/2024 | -29.85JPY | 88.57 BJPY | 2024 Q3 |
| 7/27/2023 | -17.27JPY | 101.5 BJPY | 2024 Q1 |
| 5/11/2023 | 34.14JPY | 126.06 BJPY | 2023 Q4 |
| 1/30/2023 | 26.46JPY | 149.1 BJPY | 2023 Q3 |
| 10/31/2022 | 6.26JPY | 138.34 BJPY | 2023 Q2 |
| 7/29/2022 | 20.19JPY | 143.63 BJPY | 2023 Q1 |
| 5/13/2022 | 6.06JPY | 129.8 BJPY | 2022 Q4 |
| 1/31/2022 | 30.4JPY | 144.72 BJPY | 2022 Q3 |
| 10/27/2021 | 43.48JPY | 162.13 BJPY | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Sumitomo Pharma Co stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Sumitomo Pharma Co shareholder structure
| % | Name |
|---|---|
51.75913% | |
3.58609% | |
1.90818% | |
1.81755% | |
1.76194% | |
1.69376% | |
1.45989% | |
1.45385% | |
1.26747% | |
1.02844% |
Sumitomo Pharma Co Executives and Management Board
Mr. Toru Kimura
(63)President, Chief Executive Officer, Representative Director · since 2015
Mr. Motoyuki Sakai
(62)Executive Vice President, Representative Director · since 2024
Mr. Hiroyuki Baba
(63)Managing Executive Officer · since 2015
Mr. Hideyuki Harada
Managing Executive Officer, Deputy Head of Japan Business Unit
Ms. Atsuko Higuchi
Managing Executive Officer
Sumitomo Pharma Co Supply Chain
Frequently asked questions about Sumitomo Pharma Co
The business model of Sumitomo Dainippon Pharma Co Ltd revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Sumitomo Dainippon Pharma focuses on researching and providing solutions to significant unmet medical needs. By leveraging its expertise in various therapeutic areas, the company aims to improve patients' health and well-being while contributing to society. Sumitomo Dainippon Pharma actively collaborates with partners, both domestically and internationally, to enhance its global presence and deliver effective and safe treatments to a diverse range of patients.
Sumitomo Pharma Co stock
Sumitomo Pharma Co Peer Group
Sumitomo Pharma Co Ticker
Sumitomo Pharma Co FIGI
All fundamentals and in-depth analysis of Sumitomo Pharma Co
Our stock analysis for Sumitomo Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sumitomo Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.